Latest News
From the Journals
Mutations may be detectable years before AML diagnosis
The results suggest that monitoring strategies should be studied.
From the Journals
DOACs’ safety affirmed in real-world setting
Direct oral anticoagulants were linked with lower bleeding risk, regardless of reason for use. One shone brightest.
Conference Coverage
Venetoclax with 5+2 chemo looks effective in older AML patients
STOCKHOLM – The combination of the BCL2 inhibitor and attenuated dose chemotherapy showed good early efficacy in a dose-expansion study.
From the Journals
Many actionable mutations may be missed in current testing of advanced RCC
Germline mutations in patients with advanced renal cell carcinoma may be more common than previously suspected.
In a single-center cohort of...
Conference Coverage
Trastuzumab biosimilar is equivalent on central review
CHICAGO – In a 20-country neoadjuvant trial, findings when tissue was centrally reviewed differed somewhat from those when tissue was reviewed...
Conference Coverage
DESMOPAZ: Pazopanib slows disease progression of desmoid tumors
Pazopanib elicited clinically meaningful responses in adults with progressive desmoid tumors according to RECIST 1.1 criteria, based on two...
Feature
Drug price transparency laws gain ground
At least eight states have passed laws to expose questionable pricing of prescription drugs, but critics say the measures don’t go far enough.
Feature
GOP Doctors Caucus seeks lower MIPS threshold
Lawmakers say too many physicians are excluded from the program under the current rules.
News
FDA recommends pooled Zika testing of blood donations
An exception is made for geographic areas with high risk of mosquito-borne Zika transmission.
From the Journals
PSMA-targeting docetaxel nanoparticles active, safe for mCRPC
Circulating tumor cells expressing prostate-specific membrane antigen could be a patient-selection marker.
Conference Coverage
Hydroxyurea well tolerated in longitudinal European study
WASHINGTON – Fewer than one in five adults experienced treatment-related adverse events and no secondary malignancies have been observed,...